Evidence map›Paper›PMID 34878867›Full record

ArticleAmerican journal of public health2021

Considerations for Improving Reporting and Analysis of Date-Based COVID-19 Surveillance Data by Public Health Agencies.

Ian Hennessee, Julie A Clennon, Lance A Waller, Uriel Kitron, J Michael Bryan

Abstract read
In one paragraph

Article in American journal of public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Hennessee et al. Respond.American journal of public health · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Ian HennesseeIan Hennessee is a PhD candidate with the Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA. Julie Clennon and Uriel Kitron are with the Department of Environmental Sciences, Emory University. Lance Waller is with the Department of Biostatistics and Bioinformatics, Emory University. J. Michael Bryan is with the Georgia Department of Public Health (GDPH), Atlanta.
Julie A ClennonIan Hennessee is a PhD candidate with the Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA. Julie Clennon and Uriel Kitron are with the Department of Environmental Sciences, Emory University. Lance Waller is with the Department of Biostatistics and Bioinformatics, Emory University. J. Michael Bryan is with the Georgia Department of Public Health (GDPH), Atlanta.
Lance A WallerIan Hennessee is a PhD candidate with the Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA. Julie Clennon and Uriel Kitron are with the Department of Environmental Sciences, Emory University. Lance Waller is with the Department of Biostatistics and Bioinformatics, Emory University. J. Michael Bryan is with the Georgia Department of Public Health (GDPH), Atlanta.
Uriel KitronIan Hennessee is a PhD candidate with the Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA. Julie Clennon and Uriel Kitron are with the Department of Environmental Sciences, Emory University. Lance Waller is with the Department of Biostatistics and Bioinformatics, Emory University. J. Michael Bryan is with the Georgia Department of Public Health (GDPH), Atlanta.
J Michael BryanIan Hennessee is a PhD candidate with the Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA. Julie Clennon and Uriel Kitron are with the Department of Environmental Sciences, Emory University. Lance Waller is with the Department of Biostatistics and Bioinformatics, Emory University. J. Michael Bryan is with the Georgia Department of Public Health (GDPH), Atlanta.

Funding

Infectious Diseases Across Scales Training ProgramT32AI138952 · NIAID · EMORY UNIVERSITY · PI Jacobus de Roode · 2019 to 2026
$1.8M
NIAID NIH HHS T32 AI138952
6 · The paper itself

Abstract

More than a year after the first domestic COVID-19 cases, the United States does not have national standards for COVID-19 surveillance data analysis and public reporting. This has led to dramatic variations in surveillance practices among public health agencies, which analyze and present newly confirmed cases by a wide variety of dates. The choice of which date to use should be guided by a balance between interpretability and epidemiological relevance. Report date is easily interpretable, generally representative of outbreak trends, and available in surveillance data sets. These features make it a preferred date for public reporting and visualization of surveillance data, although it is not appropriate for epidemiological analyses of outbreak dynamics. Symptom onset date is better suited for such analyses because of its clinical and epidemiological relevance. However, using symptom onset for public reporting of new confirmed cases can cause confusion because reporting lags result in an artificial decline in recent cases. We hope this discussion is a starting point toward a more standardized approach to date-based surveillance. Such standardization could improve public comprehension, policymaking, and outbreak response. (

Indexed as

Centers for Disease Control and Prevention, U.S.COVID-19Data CollectionGuidelines as TopicHumansPublic Health SurveillanceSARS-CoV-2Time FactorsUnited States

Identifiers

PMID34878867
PMCPMC8667830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.